Singletto
Singletto is a biotechnology company revolutionizing antimicrobial protection for healthcare, military, industry, and consumer applications. Their core technology, Oxafence®, leverages Antimicrobial Photodynamic Inactivation (aPDI) using light-activated dyes to generate singlet oxygen, which inactivates viruses and bacteria on treated surfaces. Founded during the COVID-19 pandemic by Drs. James Chen and Thomas Lendvay, Singletto's mission is to deliver ongoing, science-driven Active Protection™ against current and emerging biological threats. The company collaborates with global health leaders, including the WHO and CDC, and partners with manufacturers to develop and commercialize innovative products that actively destroy pathogens during use. Singletto's work is validated by a robust body of peer-reviewed research and ongoing global collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Surgical mask with FDA-cleared antimicrobial photodynamic treatment
A surgical mask product incorporating a light-activated antimicrobial treatment that has obtained U.S. regulatory clearance for virus-inactivation claims.
Surgical mask with FDA-cleared antimicrobial photodynamic treatment
A surgical mask product incorporating a light-activated antimicrobial treatment that has obtained U.S. regulatory clearance for virus-inactivation claims.
Expertise Areas
- Antimicrobial photodynamic inactivation (aPDI)
- PPE decontamination and pre-treatment
- Textile integration of photosensitizing agents
- Virology testing and pathogen challenge studies
Key Technologies
- Photodynamic therapy / antimicrobial photodynamic inactivation
- Photosensitizing dyes (e.g., methylene blue-based formulations)
- Singlet oxygen generation and photochemistry
- Textile impregnation and formulation methods
Key People
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Operating Officer
Board Member, Chief Financial Officer, Strategic Advisor
Clinical Solutions
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Operating Officer
Board Member, Chief Financial Officer, Strategic Advisor
Clinical Solutions
Investors
Debt Financing - Singletto
$65,000 funded.
Announced on 2024-01-17.
Debt Financing - Singletto
$200,000 funded.
Announced on 2023-05-08.
Debt Financing - Singletto
$50,000 funded.
Announced on 2021-08-06.
Convertible Note - Singletto
$1,000,000 funded.
Announced on 2020-10-05.
Debt Financing - Singletto
$65,000 funded.
Announced on 2024-01-17.
Debt Financing - Singletto
$200,000 funded.
Announced on 2023-05-08.
Debt Financing - Singletto
$50,000 funded.
Announced on 2021-08-06.
Convertible Note - Singletto
$1,000,000 funded.
Announced on 2020-10-05.
News & Updates
Singletto's Oxafence technology received FDA clearance for use in ProGear ASTM L3 Surgical Masks, now available in the U.S. and New Zealand.
The WHO-led DeMaND study, co-authored by Singletto's leadership, was published in Infection Control & Hospital Epidemiology, validating the efficacy of methylene blue and light for PPE decontamination.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer, was recognized as a Top Doctor by Seattle Magazine.
GeekWire highlighted Singletto as a lead story, focusing on the FDA approval of its Oxafence Active Protection technology for surgical masks and the company's plans for expansion.
Peer-reviewed research, including studies by Singletto co-founders, confirmed the efficacy of Antimicrobial Photodynamic Inactivation (aPDI) against a range of dangerous viruses, supporting the core technology behind Oxafence.
An article by CEO John Bjornson introduces aPDI technology, recaps the WHO DeMaND study, and advocates for better PPE protection.
Singletto's Oxafence technology received FDA clearance for use in ProGear ASTM L3 Surgical Masks, now available in the U.S. and New Zealand.
The WHO-led DeMaND study, co-authored by Singletto's leadership, was published in Infection Control & Hospital Epidemiology, validating the efficacy of methylene blue and light for PPE decontamination.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer, was recognized as a Top Doctor by Seattle Magazine.
GeekWire highlighted Singletto as a lead story, focusing on the FDA approval of its Oxafence Active Protection technology for surgical masks and the company's plans for expansion.
Peer-reviewed research, including studies by Singletto co-founders, confirmed the efficacy of Antimicrobial Photodynamic Inactivation (aPDI) against a range of dangerous viruses, supporting the core technology behind Oxafence.
An article by CEO John Bjornson introduces aPDI technology, recaps the WHO DeMaND study, and advocates for better PPE protection.